188 related articles for article (PubMed ID: 30792002)
1. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
[TBL] [Abstract][Full Text] [Related]
2. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
Pezo RC; Chen TW; Berman HK; Mulligan AM; Razak AA; Siu LL; Cescon DW; Amir E; Elser C; Warr DG; Sridhar SS; Yu C; Wang L; Stockley TL; Kamel-Reid S; Bedard PL
Breast Cancer Res Treat; 2018 Feb; 168(1):159-168. PubMed ID: 29177603
[TBL] [Abstract][Full Text] [Related]
3. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Spreafico A; Oza AM; Clarke BA; Mackay HJ; Shaw P; Butler M; Dhani NC; Lheureux S; Wilson MK; Welch S; Zhang T; Yu C; Stockley T; Siu LL; Kamel-Reid S; Bedard PL
Gynecol Oncol; 2017 Feb; 144(2):250-255. PubMed ID: 28062115
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
[TBL] [Abstract][Full Text] [Related]
6. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers.
Somasegar S; Hoppenot C; Kuchta K; Sereika A; Khandekar J; Rodriguez G; Moore E; Hurteau J; Vogel TJ
Gynecol Oncol; 2021 Nov; 163(2):220-228. PubMed ID: 34511240
[TBL] [Abstract][Full Text] [Related]
8. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
[TBL] [Abstract][Full Text] [Related]
9. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
10. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Penson RT; Sales E; Sullivan L; Borger DR; Krasner CN; Goodman AK; del Carmen MG; Growdon WB; Schorge JO; Boruta DM; Castro CM; Dizon DS; Birrer MJ
Gynecol Oncol; 2016 Apr; 141(1):108-12. PubMed ID: 27016236
[TBL] [Abstract][Full Text] [Related]
11. Initiation of a formalized precision medicine program in gynecologic oncology.
Gunderson CC; Rowland MR; Wright DL; Andrade KL; Mannel RS; McMeekin DS; Moore KN
Gynecol Oncol; 2016 Apr; 141(1):24-8. PubMed ID: 27016225
[TBL] [Abstract][Full Text] [Related]
12. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
14. Impact of molecular testing in clinical practice in gynecologic cancers.
Huang M; Hunter T; Slomovitz B; Schlumbrecht M
Cancer Med; 2019 May; 8(5):2013-2019. PubMed ID: 30848097
[TBL] [Abstract][Full Text] [Related]
15. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
Taghizadeh H; Mader RM; Müllauer L; Aust S; Polterauer S; Kölbl H; Seebacher V; Grimm C; Reinthaller A; Prager GW
Oncologist; 2020 Jul; 25(7):e1060-e1069. PubMed ID: 32369643
[TBL] [Abstract][Full Text] [Related]
16. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
17. MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial.
Okuma HS; Yonemori K; Narita SN; Sukigara T; Hirakawa A; Shimizu T; Shibata T; Kawai A; Yamamoto N; Nakamura K; Nishida T; Fujiwara Y
Clin Pharmacol Ther; 2020 Sep; 108(3):596-605. PubMed ID: 32112563
[TBL] [Abstract][Full Text] [Related]
18. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
Nie Q; Omerza G; Chandok H; Prego M; Hsiao MC; Meyers B; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rowe S; Rueter J; Reddi HV
Cancer Genet; 2020 Apr; 242():25-34. PubMed ID: 31992506
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
